Ionis Interest Expense vs Research Development Analysis
IONS Stock | USD 37.99 0.01 0.03% |
Ionis Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Ionis Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ionis Pharmaceuticals is a good investment. Please check the relationship between Ionis Pharmaceuticals Interest Expense and its Research Development accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.
Interest Expense vs Research Development
Interest Expense vs Research Development Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ionis Pharmaceuticals Interest Expense account and Research Development. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Ionis Pharmaceuticals' Interest Expense and Research Development is 0.57. Overlapping area represents the amount of variation of Interest Expense that can explain the historical movement of Research Development in the same time period over historical financial statements of Ionis Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Ionis Pharmaceuticals' Interest Expense and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Expense of Ionis Pharmaceuticals are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Interest Expense i.e., Ionis Pharmaceuticals' Interest Expense and Research Development go up and down completely randomly.
Correlation Coefficient | 0.57 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Research Development
Most indicators from Ionis Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ionis Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.At this time, Ionis Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 33.9 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.16 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 829M | 984M | 1.1B | 1.2B | Cost Of Revenue | 11M | 14M | 9.1M | 8.7M |
Ionis Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Ionis Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ionis Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 3.2B | 2.4B | 2.6B | 2.5B | 3.0B | 3.1B | |
Short Long Term Debt Total | 710M | 749M | 1.2B | 1.3B | 1.5B | 1.5B | |
Other Current Liab | 136.9M | (128.4M) | 127.6M | 195.5M | 217.8M | 228.7M | |
Total Current Liabilities | 273M | 290M | 241M | 312M | 448.1M | 470.5M | |
Total Stockholder Equity | 1.5B | 843M | 772M | 573M | 386.7M | 265.7M | |
Property Plant And Equipment Net | 154M | 181M | 178M | 256M | 242.9M | 255.1M | |
Net Debt | (1.8B) | (1.1B) | (954M) | (642M) | 1.1B | 1.1B | |
Retained Earnings | (707.5M) | (1.2B) | (1.2B) | (1.4B) | (1.8B) | (1.7B) | |
Cash | 2.5B | 1.9B | 2.1B | 2.0B | 399.3M | 534.5M | |
Non Current Assets Total | 512M | 260M | 267M | 331M | 348.2M | 365.6M | |
Non Currrent Assets Other | 358M | 51.1M | 60.0M | 34.6M | 62.3M | 34.5M | |
Cash And Short Term Investments | 2.5B | 1.9B | 2.1B | 2.0B | 2.3B | 2.4B | |
Common Stock Shares Outstanding | 142.9M | 139.6M | 141.0M | 141.8M | 143.2M | 83.9M | |
Liabilities And Stockholders Equity | 3.2B | 2.4B | 2.6B | 2.5B | 3.0B | 3.1B | |
Non Current Liabilities Total | 1.3B | 1.3B | 1.6B | 1.6B | 2.2B | 2.3B | |
Other Current Assets | 158M | 162M | 168M | 190M | 184.4M | 193.7M | |
Other Stockholder Equity | 2.2B | 2.1B | 2.0B | 2.1B | 2.2B | 2.3B | |
Total Liab | 1.5B | 1.5B | 1.8B | 2.0B | 2.6B | 2.7B | |
Total Current Assets | 2.7B | 2.1B | 2.3B | 2.2B | 2.6B | 2.8B | |
Short Term Debt | 2.0M | 293.2M | 3.5M | 7.5M | 53.2M | 55.8M | |
Intangible Assets | 24.0M | 25.7M | 27.9M | 29.0M | 33.4M | 24.2M | |
Accounts Payable | 16.1M | 17.2M | 11.9M | 17.9M | 26.0M | 27.3M | |
Net Receivables | 63M | 76M | 62M | 26M | 97.8M | 102.7M | |
Property Plant And Equipment Gross | 153.7M | 181.1M | 280.7M | 256M | 339.7M | 356.7M | |
Accumulated Other Comprehensive Income | (25.3M) | (21.1M) | (32.7M) | (57.5M) | (32.6M) | (31.0M) | |
Short Term Investments | 1.8B | 1.5B | 1.2B | 1.7B | 1.9B | 2.0B | |
Other Assets | 310.6M | 78.0M | 319M | 35.0M | 40.2M | 57.3M | |
Long Term Debt | 770.0M | 515.7M | 1.2B | 1.2B | 1.2B | 1.3B | |
Property Plant Equipment | 153.7M | 181.1M | 178.1M | 74.3M | 85.4M | 79.6M | |
Other Liab | 490.1M | 424M | 352M | 287.8M | 330.9M | 170.0M | |
Current Deferred Revenue | 118M | 108M | 98M | 91M | 151.1M | 158.7M | |
Inventory | 18.2M | 22.0M | 24.8M | 22.0M | 28.4M | 29.8M | |
Net Tangible Assets | 1.4B | 815.4M | 742.7M | 572.9M | 658.8M | 531.9M | |
Retained Earnings Total Equity | (707.5M) | (1.2B) | (1.2B) | (1.4B) | (1.3B) | (1.4B) | |
Long Term Debt Total | 770.0M | 515.7M | 1.2B | 1.2B | 1.4B | 1.4B | |
Capital Surpluse | 2.2B | 2.1B | 2.0B | 2.1B | 2.4B | 1.7B |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Ionis Stock analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Stocks Directory Find actively traded stocks across global markets | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Ionis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ionis Pharmaceuticals. If investors know Ionis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ionis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.44) | Earnings Share (2.67) | Revenue Per Share 5.397 | Quarterly Revenue Growth (0.08) | Return On Assets (0.08) |
The market value of Ionis Pharmaceuticals is measured differently than its book value, which is the value of Ionis that is recorded on the company's balance sheet. Investors also form their own opinion of Ionis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ionis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ionis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ionis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ionis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ionis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ionis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.